Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600870 · ClinicalTrials.gov registry record · Phase 1
Midodrine in Hepatopulmonary Syndrome
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03600870: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03600870 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03600870, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms.
Interventions
- DRUG Midodrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03600870
The ClinicalTrials.gov registry entry for NCT03600870 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Midodrine is the first listed.
NCT03600870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03600870 about?
NCT03600870 is a clinical study titled "Midodrine in Hepatopulmonary Syndrome". This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms.
What is the current status of trial NCT03600870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-08-02. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03600870?
The interventions under investigation include: Midodrine (DRUG).
Who is sponsoring clinical trial NCT03600870?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.